# MariMed grew wholesale revenue 11% by opening new state markets, sixth straight year of positive EBITDA

*Cannabis brand scaled distribution without burning cash, using state-by-state wholesale to compound revenue at modest cost.*

By **Jenny Huang Goodman MPA MSc MHSA, Principal** — The Stash Edge, Hako Shikin LLC.
Published 2026-07-26.

Canonical: https://www.pops4.com/stash/articles/marimed-2026-07-26t21-4
Subject: MariMed
Tags: wholesale, distribution, licensing, state expansion, cannabis, marimed

---

MariMed reported wholesale revenue up **11%** in 2025 while entering new state markets and achieving a sixth consecutive year of positive adjusted EBITDA, according to MSN. The Massachusetts-based cannabis company grew distribution by licensing brands into new territories rather than building out capital-intensive retail or cultivation in each market, a model that allows controlled expansion on existing margin.

The company used wholesale partnerships to place branded products—edibles, vapes, flower—on retail shelves in markets where it holds no manufacturing footprint. MariMed does not disclose the exact number of new states entered in 2025, but CEO Jon Levine confirmed that state expansion contributed to the **11%** wholesale lift. The firm reported overall revenue growth of **1%** for the year, indicating the wholesale channel outpaced other segments while the business held flat or retreated elsewhere.

The mechanism is state-by-state distribution arbitrage. Cannabis brands cannot ship across state lines, so each new market requires either a facility build or a licensing deal with a local manufacturer. MariMed chose licensing. It signs a white-label agreement or co-packing arrangement with an in-state partner, ships the formulation and brand standards, then collects a royalty or wholesale margin on every unit sold. The local partner handles compliance, manufacturing, and often distribution to retail. MariMed pays no rent, no equipment lease, and carries no inventory risk in the new state. The wholesale revenue shows up with minimal incremental opex, which is why the company can report six years of positive adjusted EBITDA while still expanding.

This model works when the brand has pull. A retailer in Illinois or Maryland will stock a MariMed SKU if consumers recognize the brand from Massachusetts or if the product fills a gap the local assortment lacks. The licensing partner gets a proven SKU without R&D spend. MariMed gets distribution without capital. Both collect margin. The constraint is brand strength: a no-name edible gets no shelf space, and the licensing partner walks.

A small physical-product brand runs the same play by targeting geographic or channel gaps where a partner has distribution but no comparable product. Identify a region or retailer where your category does well but your brand does not yet appear. Find a distributor, sales rep group, or complementary brand that already has the shelf relationship. Offer a white-label or co-branded SKU with a revenue share: the partner takes **40-60%** of wholesale, you handle formulation and brand assets, they handle fulfilment and sell-in. You pay no upfront fee, no slotting, no inventory holding cost. The partner pays you only when units move. Start with one region. If the test works, repeat in the next.

Test costs: product samples for the pitch meeting, digital sell sheets, a simple licensing agreement from a contract template. Total outlay under **$500** for a regional trial. MariMed's wholesale revenue grew **11%** because it found partners in states where cannabis demand existed and retail was fragmented. A candle brand, a hot sauce, a dog treat does the same: find the underserved zip codes, the regional chain that lacks your category, the rep who knows the buyer.

The six-year EBITDA streak signals disciplined expansion. MariMed did not chase top-line growth at any cost. It entered only markets where a partner existed and unit economics penciled. The wholesale channel scales at lower gross margin than owned retail but requires a fraction of the capital and carries none of the lease or labor tail. For a physical-product brand, the lesson is clear: distribution expansion does not require a warehouse lease or a sales team. It requires a product someone else can sell and a split both sides accept.

## The takeaway

MariMed grew wholesale 11% by licensing into new states with local partners, scaling revenue without capital spend or EBITDA loss.

---

## Publisher

**Hako Shikin LLC** — Virginia Beach, Virginia. Founded 1997. ASI 217876 · DUNS 18-204-6339.
Principal and author: **Jenny Huang Goodman MPA MSc MHSA**.

- Author: https://www.huanggoodman.com/about
- LLM context: https://www.pops4.com/stash/llms.txt
- MCP endpoint, for AI agents: https://mcp.pops4.com/mcp
- Client dashboard: https://dashboard.pops4.com/
- Catalogue: 70,000+ products, 200+ brands